Omeros Corporation (OMER) - News Archive

In a significant advancement in the treatment of transplant-associated thrombotic microangiopathy (TA-TMA), Omeros Corporation (Nasdaq: OMER) announced the publication of a pivotal peer-reviewed manuscript in the Americ...

Navigating Future Therapeutics: Omeros Corporation s Advances in TA-TMA and PNH In recent months, Omeros Corporation (Nasdaq: OMER) has made significant strides in advancing its therapeutic pipeline. Key developments in...

Omeros Corporation s investigational compound, Zaltenibart (OMS906), has entered an advanced stage of clinical evaluation for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), with the activation of clinical t...

In recent developments within the pharmaceutical sector, Omeros Corporation has made significant strides in the treatment of complement-mediated disorders. The company has updated its ongoing Phase 3 clinical trial prog...

In an encouraging move for advancing innovative treatments in rare diseases, Omeros Corporation (Nasdaq: OMER) recently announced several significant updates regarding its novel complement inhibitors: zaltenibart and na...

Omeros Corporation s Recent Developments in TA-TMA TreatmentOmeros Corporation, a Seattle-based biopharmaceutical company, has recently generated significant buzz within the medical and investment communities by announc...

Omeros Achieves Pivotal Milestone with Narsoplimab in TA-TMA Treatment In a groundbreaking announcement, Omeros Corporation (Nasdaq: OMER) revealed that its lead investigational therapy, narsoplimab, has successfully me...

Innovative Biologics Achieve Milestones: Omeros Corporation Nears Resubmission of BLA for Pioneering Antibody Treatment in TA-TMA SEATTLE, WA In a significant development for both the field of hematology and the biophar...

: Omeros Corporation, a biopharmaceutical company focused on therapeutics for immunologic disorders, has announced significant financial results and corporate developments for the second quarter of 2024. This article sy...

Seattle-based biotech company strengthens its balance sheet and prepares for potential commercialization. Recent Financial Performance: Second Quarter 2024 SEATTLE Omeros Corporation (NASDAQ: OMER), a clinical-stage bio...

Omeros Corporation: Navigating Breakthroughs and Financial Landscapes in 2024 A Dual Focus on Financial Performance and Clinical ProgressIn a year marked by both fiscal focus and groundbreaking clinical milestones, Omer...

Omeros Corporation Strengthens Balance Sheet and Extends Debt Maturity into 2028Seattle-based biopharmaceutical company, Omeros Corporation, has recently announced a series of strategic financial transactions that not o...

In an announcement made today, Omeros Corporation (NASDAQ: OMER) revealed that it will be sharing its financial results for the first quarter and year ended March 31, 2024, on Wednesday, May 15, 2024, after the market c...

Omeros Corporation (Nasdaq: OMER), a renowned biopharmaceutical company, recently announced that interim analysis data from its ongoing Phase 2 study of OMS906, an investigational inhibitor of MASP-3, has been selected...